Newsfeeds Archive - Page 8 of 194

1 minute read

News

Tenable Vulnerability Management And Tenable Web App Scanning, Have Been Successfully Assessed At A Protected Level By The Information Security Registered Assessors Program In Australia

December 10, 5:15 PM

Tenable® , the Exposure Management company, today announced that two of its solutions, Tenable Vulnerability Management and Tenable Web App Scanning, have been successfully assessed at a 'PROTECTED' level by

TENB

1 minute read

Events
News

Centessa Pharmaceuticals Announced New Data From Additional 52-Weeks of Continuous Treatment From Third Year (Part 5) Of Ongoing Phase 2a Study Of SerpinPC For Treatment Of Hemophilia At 2023 ASH Meeting

By Charles Gross

December 10, 1:57 PM

Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of

CNTA

1 minute read

Events
News

Molecular Partners Presented Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial Of MP0533 For Patients With Relapsed/Refractory AML And AML/MDS At 2023 ASH Meeting

By Charles Gross

December 10, 1:51 PM

Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today presented positive initial clinical data from its

MOLN

1 minute read

Uncategorized

Regeneron Announced Sunday Updated Odronextamab Data From Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep And Durable Responses And Potential Of ctDNA To Predict Long-term Outcomes At 2023 ASH Meeting

By Charles Gross

December 10, 1:49 PM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced new and updated data for odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The data from the pivotal Phase 2

REGN

1 minute read

FDA
News

Belite Bio Received Approval To Initiate Tinlarebant Phase 3 Clinical Trial For GA in Switzerland

By Charles Gross

December 10, 1:45 PM

Belite Bio, Inc (NASDAQ:BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs,

BLTE

1 minute read

Events
News

Bristol Myers Squibb On Saturday Presented Primary Efficacy, Safety Analysis of the Phase 3 COMMANDS Trial Of Reblozyl For Treatment Of Anemia In Erythropoiesis Stimulating Agent-Naïve Patients With Lower-Risk Myelodysplastic Syndromes At 2023 ASH Meet…

By Charles Gross

December 10, 11:15 AM

Bristol Myers Squibb (NYSE:BMY) announced updated results from the primary analysis of the Phase 3 COMMANDS trial, comparing Reblozyl® (luspatercept-aamt) versus epoetin alfa for the treatment of anemia in

BMY

1 minute read

Events
News

Biomea Fusion Announced Saturday Near Doubling The Percentage Of Patients With Durable HbA1c Reduction In the 200 mg Dose Cohorts

By Charles Gross

December 10, 11:08 AM

Biomea Fusion, Inc. (“Biomea”) (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with

BMEA

1 minute read

Events
News

Aptose Tuspetinib Clinical Data Featured In Oral Presentation Saturday At 2023 ASH Meeting; Said TUS/VEN Combination Active Across Broad Populations Of AML And Demonstrates 25% Complete Response Rate Among All-comers, Including 20% CRc In Wildtype AML

By Charles Gross

December 10, 9:14 AM

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic

APTO

1 minute read

Events
News

Pfizer Announced Saturday Marstacimab Phase 3 Data Presented At ASH 2023 Demonstrate Significant Bleed Reduction In Hemophilia A And B

By Charles Gross

December 10, 8:34 AM

Pfizer Inc. (NYSE:PFE) presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia

PFE

2 minute read

Events
News

Autolus Therapeutics Presented Clinical Data Updates Saturday At 2023 ASH Meeting

By Charles Gross

December 10, 8:32 AM

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces two oral presentations and two poster presentations at the

AUTL